Method for the purification of lansoprazole
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsClaude Singer, Anita Liberman, Irena Veinberg, Nina Finkelstein, Tamar Nidam
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for preparing a substantially pure lansoprazole containing less than about 0.2% (wt/wt) impurities including sulfone/sulfide derivatives. The present invention also provides a process for recrystallizing lansoprazole to obtain a lansoprazole containing less than about 0.1% (wt/wt) water.
Claims3
A purified 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, comprising 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole and at least one of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]thio]-1H-benzimidazole and 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfonyl]-1H-benzimidazole, wherein the 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]thio]-1H benzimidazole and 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfonyl]-1H-benzimidazole are present in a combined amount of less than 0.20%, wt/wt, wherein the purified 2-[[[3-methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole comprises less than 0.1% wt/wt water.
Dependencies are inferred from the claim text.